Identify and evaluate the new licensing and acquisition opportunities that are critical to maintaining a healthy product development pipeline. APLUSA recognizes that competition for promising agents is fierce, and that you need to be able to move quickly and decisively once you’ve identified a compound with potential.

APLUSA partners with you to evaluate business development and in-licensing (BD&L) opportunities for both overall portfolios fit as well as long-term market potential.

APLUSA’s qualitative and quantitative approaches help you get answers to critical business development and in-licensing questions fast.

APLUSA‘s proven tools, such as Patient Chart studies, Augmented Insights, and Estimated Share of Preference (ESOP™) can help you to determine:

Opportunity Prioritization

Assessing the relative strength of several opportunities to determine which one holds the greatest potential for your company.

Portfolio Fit

Determining how well a given compound might fit into your existing portfolio, including consistency of clinical performance as well as potential for cannibalization of your existing brands.

Market Potential Assessment

Quantifying the overall market potential of a compound based on match with current unmet treatment needs, receptivity among healthcare providers, and potential payer controls impacting uptake.

With the high cost of product development and commercialization, you need certainty that your product has strong potential in the markets where you seek to launch. AplusA is your partner in market opportunity, sizing, and potential assessment so that you can have confidence that you’re investing in the right product at the right time. We integrate prescriber and patient insights, market analysis, therapeutic expertise, and deep industry knowledge to enable you to discover new market opportunities, evaluate their potential, and create strategies for launching into that new market.

APLUSA has qualitative and quantitative expertise in several dimensions of product potential assessment.

APLUSA‘s expertise in Patient Chart studies as well as our extensive portfolio of Syndicated Solutions means we are ideally placed to help you with:

Market Sizing

Estimating not only the total patient population appropriate for your product, but also the proportion of physicians likely to prescribe or use your product.

Needs Assessment

Identifying the type and scope of unmet needs in patient treatment that might be addressed by your product.

Profile Evaluation

Assessing the viability of your product as well as “must have” characteristics among key stakeholders, including physicians and payers, based on a preliminary target product profile.

Portfolio Assessment

Determining how this new product fits into your existing treatment portfolio, including the degree to which the new product will strengthen or cannibalize share.

New product discovery or development is the lifeblood of healthcare companies. Given the cost of development as well as the long-term horizons involved in getting a product through approval and to market, careful portfolio planning must be undertaken to understand the position that any new product will occupy in your overall offering.

APLUSA has qualitative and quantitative expertise that give you the high-level overview of your portfolio and enable you to understand the impact that introducing a new product will have.

APLUSA‘s expertise in Patient Chart studies as well as our extensive portfolio of Syndicated Solutions are ready to help you with:

Needs Assessment

Determining whether the new product fits a defined treatment need in the market.

Profile Evaluation

Assessing the viability of your product and well as “must have” characteristics among key stakeholders, including physicians and payers, based on a preliminary target product profile.

Share Estimation

Quantifying the potential usage of the product, including cannibalization of existing portfolio assets and share challenges from competitive brands.

Long-Term Planning

5-, 10- and 15-year estimates of the overall portfolio’s performance, incorporating anticipated changes in treatment and assessment of competitive agents in development.